[go: up one dir, main page]

WO2006012577A3 - Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake - Google Patents

Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake Download PDF

Info

Publication number
WO2006012577A3
WO2006012577A3 PCT/US2005/026192 US2005026192W WO2006012577A3 WO 2006012577 A3 WO2006012577 A3 WO 2006012577A3 US 2005026192 W US2005026192 W US 2005026192W WO 2006012577 A3 WO2006012577 A3 WO 2006012577A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
food intake
quinazolinone derivatives
derivatives useful
glucose homeostasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/026192
Other languages
French (fr)
Other versions
WO2006012577A2 (en
Inventor
Joachim Rudolph
Stephen O'connor
Philip Coish
Philip Wickens
Georgiy Bondar
Chih-Yuan Chuang
Philip Ramsden
Derek Lowe
Donald Bierer
Libing Chen
Wenlang Fu
Uday Khire
Xiao-Gao Liu
Andrea Mcclure
Lei Wang
Lin Yi
William Esler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006012577A2 publication Critical patent/WO2006012577A2/en
Publication of WO2006012577A3 publication Critical patent/WO2006012577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to substituted quinazolinone derivatives, compositions, and methods for treating diabetes, obesity and related disorders, and regulation of food intake (e.g., stimulation and suppression).
PCT/US2005/026192 2004-07-22 2005-07-22 Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake Ceased WO2006012577A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59080404P 2004-07-22 2004-07-22
US60/590,804 2004-07-22

Publications (2)

Publication Number Publication Date
WO2006012577A2 WO2006012577A2 (en) 2006-02-02
WO2006012577A3 true WO2006012577A3 (en) 2006-09-28

Family

ID=35786753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026192 Ceased WO2006012577A2 (en) 2004-07-22 2005-07-22 Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake

Country Status (1)

Country Link
WO (1) WO2006012577A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838296B1 (en) 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
CA2636981A1 (en) * 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
CN101600698B (en) * 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 Quinazolinone and isoquinolinone acetamide derivatives
AU2007345526B2 (en) 2007-02-01 2013-02-28 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
CN101531638B (en) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 Compounds useful as estrogen-related receptor modulators and uses thereof
US20110065671A1 (en) 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2009158404A1 (en) * 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CN101628913B (en) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 Compounds useful as estrogen-related receptor modulators and uses thereof
FR2938538B1 (en) * 2008-11-17 2011-08-05 Univ Nice Sophia Antipolis PROCESS FOR THE PREPARATION OF ACIDS AND BORONIC ESTERS IN THE PRESENCE OF METAL MAGNESIUM
JP2012051803A (en) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd Production method of cyclic aminobenzoic acid ester derivative
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
KR101709492B1 (en) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
ES2706651T3 (en) 2009-04-22 2019-03-29 Resverlogix Corp New anti-inflammatory agents
WO2011075699A2 (en) * 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
SI2773354T1 (en) 2011-11-01 2019-08-30 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
KR20150096794A (en) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 Novel heterocyclic compounds as bromodomain inhibitors
GB201313664D0 (en) * 2013-07-31 2013-09-11 Univ Cardiff Bcl-3 inhibitors
KR102662814B1 (en) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 Compositions and treatment methods for treating complement-related diseases
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
WO2018184115A1 (en) * 2017-04-06 2018-10-11 London Health Sciences Centre Research Inc. Quinazolinone derivatives useful for imaging
WO2019104324A1 (en) * 2017-11-27 2019-05-31 The Scripps Research Institute Ghsr1a antagonist for prader-willi syndrome treatment
CN110698392A (en) * 2019-09-09 2020-01-17 中国农业大学 A kind of bisamide compound and its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033792A1 (en) * 1997-01-31 1998-08-06 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033792A1 (en) * 1997-01-31 1998-08-06 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAKER B.R. ET AL.: "An Antimalarial Alkaloid From Hydrangea. IV. Functional Derivatives of 3-Alkyl-4-Quinazolones", J. ORG. CHEM., vol. 17, 1952, pages 35 - 51 *

Also Published As

Publication number Publication date
WO2006012577A2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
WO2005119627A3 (en) Personal nutrition control devices
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005046603A3 (en) Pyridine compounds
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2007104789A3 (en) Amylin derivatives
WO2006020959A3 (en) Substituted benzofused heterocycles
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same
WO2009068246A3 (en) Methods of treating obesity and metabolic disorders
WO2006034154A3 (en) Salts of 5-azacytidine
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase